ArticleCardiovascular intervention and therapeutics2025
The relationship between chronic expansion of self-expandable valves and paravalvular leakage in transcatheter aortic valve implantation.
Article in Cardiovascular intervention and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcatheter Aortic Valve Replacement in Patients With Aortic Stenosis and Cardiogenic Shock.Circulation reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paravalvular leakage (PVL) is a clinical concern in transcatheter aortic valve implantation (TAVI). Although PVL has been reported to gradually decrease after self-expandable valves (SEVs) implantation, the mechanism remains unclear. Furthermore, while gradual expansion of SEVs has been documented, studies assessing their morphological changes during the chronic phase are lacking. This study aims to evaluate whether SEVs expansion occurs during follow-up and if this expansion correlates with a reduction in PVL. We included 60 patients who underwent TAVI using SEVs (Evolut PRO/PRO+/FX) from October 2020 to August 2024. Morphological findings of SEVs were assessed using computed tomography (CT), and PVL was evaluated at discharge and chronic phase post-TAVI. PVL was graded on a five-point scale via transthoracic echocardiography, and the area ratio, defined as the ratio of the basal area of the implanted SEVs to that of phantom valves measured by CT, served as the index of SEVs expansion. Chronic expansion of SEVs was observed in all cases, with the area ratio increasing from 0.59 at discharge to 0.64 at the follow-up (P < 0.05). Among the 60 patients, 44 exhibited mild or greater PVL, with 17 showing improvement at the chronic phase. The degree of valve expansion (area ratio at chronic phase/area ratio at discharge) was significantly greater in the PVL improvement group compared to the non-improvement group (1.11 vs. 1.06, P < 0.05). This study demonstrates that SEVs expand during the chronic phase after TAVI, which could contribute to the reduction of PVL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.